| 摘要 |
The invention relates to NEP inhibitors for treating cardiovascular disorder s. Preferred NEP inhibitors are compounds of formula (I) wherein R1 is C,- C6alkyl, Ci-C6alkoxyC,~C3alkyl or C,-C6alkoxyC,-C6alkoxyC,-C3alkyl; R2 is hydrogen or C,-C6alkyl; L is a three 5 atom linkage selected from -CH2-X-CH2 - and -CH2-CH2-X- where the right hand side of the linkage is attached to R3 a nd where X is oxygen, sulfur or methylene; R3 is phenyl or aromatic heterocycly l, either of which may be independently substituted by one or more groups selected from: C1-C6alkyl, halo, haloC,-C6alkyl, C,-C6alkoxy, haloC1-C6alkox y, C1-~C6alkylthio, haloC,-C6alkylthio and nitrile; and R4 and R5 are either bo th hydrogen, or one of R4 and R5 is hydrogen and the other is a biolabile ester - forming group that in the body of a patient is replaced by hydrogen.
|
